Skip to main content

11 Result(s)

within Brian G. M. Durie Remove this filter Medicine & Public Health Remove this filter Oncology Remove this filter

and

  1. Article

    Open Access

    Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

    Daratumumab plus lenalidomide and dexamethasone (D-Rd) and bortezomib plus lenalidomide and dexamethasone (VRd) are commonly used treatment combinations for transplant-ineligible (TIE) patients with newly diag...

    Brian G. M. Durie, Shaji K. Kumar, Eric M. Ammann, Alex Z. Fu… in Advances in Therapy (2024)

    Download PDF (629 KB) View Article

  2. Article

    Open Access

    Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

    Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM); however, more data are needed on its impact on health-related quality of life (HRQoL). Pre...

    Rafat Abonour, Lynne Wagner, Brian G.M. Durie, Sundar Jagannath… in Annals of Hematology (2018)

    Download PDF (744 KB) View Article

  3. No Access

    Article

    Observational study of multiple myeloma in Latin America

    Relatively little is known about the outcomes of multiple myeloma in Latin America, a world region where incorporation of novel agents is generally slow. In the current retrospective-prospective study, we aime...

    Vania T. M. Hungria, Angelo Maiolino, Gracia Martinez… in Annals of Hematology (2017)

  4. No Access

    Article

    Awareness, concern, and communication between physicians and patients on bone health in cancer

    This study aims to explore physician–patient communications about bone metastases and cancer treatment-induced bone loss (CTIBL).

    Debu Tripathy, Brian G. M. Durie, Beatrice Mautner… in Supportive Care in Cancer (2014)

  5. No Access

    Chapter

    The Role of Anatomic and Functional Imaging in Myeloma

    Brian G.M. Durie in Myeloma Therapy (2008)

  6. No Access

    Article

    Phase II evaluation of bisantrene in refractory multiple myeloma

    Brian G. M. Durie, John Crowley, Charles A. Coltman Jr.… in Investigational New Drugs (1991)

  7. No Access

    Chapter

    Workshop on growth factors

    The ‘Workshop on Growth Factors’ which took place at the Lugano Lymphoma Conference on June 8, 1990, included a presentation by Michael Sporn on the concept that loss of inhibitory control mechanisms may be im...

    Professor Derek Crowther, Michael B. Sporn, Anita B. Roberts… in Annals of Oncology (1991)

  8. No Access

    Chapter and Conference Paper

    Cytogenetic Abnormalities in Multiple Myeloma

    Cytogenic studies in multiple myeloma have been very difficult because of the predominantly low proliferative activity in this disease (1-7). In the series reported to date the most commonly affected chromosomes ...

    Brian G. M. Durie, Elizabeth E. Vela… in Epidemiology and Biology of Multiple Myelo… (1991)

  9. No Access

    Chapter

    Macrophages as an Important Source of Paracrine IL6 in Myeloma Bone Marrow

    Interleukin 6 (IL6) is a pleiotropic cytokine which has been shown to be a very potent growth factor for myeloma cells, particularly cells derived from patients with aggressive clinical disease (1,2). Although it...

    Brian G. M. Durie, Elizabeth E. Vela… in Mechanisms in B-Cell Neoplasia 1990 (1990)

  10. No Access

    Article

    Treatment of patients with refractory myelogenous leukemia with BCOMM [1,3-bis-chloro(2-chloroethyl)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methyl-glyoxal bis-guanylhydrazone (MGBG)]

    Ten patients with AML refractory to anthracyclines and cytosine arabinoside were treated with vincristine 1.4 mg/m2 and methotrexate (MTX) 2.5 gm/m2 by intravenous (IV) bolus on day 1 [citrovorum factor (CF) resc...

    Terence S. Herman, Brian G. M. Durie… in Cancer Chemotherapy and Pharmacology (1982)

  11. No Access

    Article

    Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy

    Objective methods have been developed to quantitate results of the in vitro human tumor stem cell assay, the degree of the association between the in vitro assay and clinical response as well as the likelihood...

    Thomas E. Moon, Sydney E. Salmon, Carolyn S. White… in Cancer Chemotherapy and Pharmacology (1981)